Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
DNA pharmaceuticals [[electronic resource] ] : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef
| DNA pharmaceuticals [[electronic resource] ] : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2005 |
| Descrizione fisica | 1 online resource (277 p.) |
| Disciplina |
615.372
616.0796 |
| Altri autori (Persone) | SchleefM (Martin) |
| Soggetto topico |
DNA vaccines
Gene therapy Immunotherapy |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-85409-X
9786610854097 3-527-60753-6 3-527-60700-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
DNA Pharmaceuticals; Preface; Contents; List of Contributors; Abbreviations; 1 DNA Vaccines - An Overview; 1.1 Rationale for DNA Vaccines; 1.2 Preclinical Proof of Concept; 1.3 Clinical Trials; 1.4 Second-Generation Vaccines; 1.5 Conclusions; References; 2 DNA as a Pharmaceutical - Regulatory Aspects; 2.1 Introduction; 2.2 Quality Requirements for DNA used as a Gene Therapy Product; 2.2.1 Introduction; 2.2.2 Production and Purification; 2.2.2.1 Raw Materials; 2.2.2.2 Antibiotics; 2.2.2.3 Solvents; 2.2.2.4 Fermentation; 2.2.2.5 Purification; 2.2.3 Cell Banking System Procedures
2.2.3.1 Generation and Characterization of Master and Working Cell Banks2.2.4 Product Characterization and Quality Criteria; 2.2.4.1 Identity; 2.2.4.2 Purity; 2.2.4.3 Adventitious Agents; 2.2.4.4 Potency; 2.3 Safety Studies for Clinical Trials; 2.3.1 General Considerations; 2.3.2 Conduct of Preclinical Safety Studies; 2.3.2.1 Regulations; 2.3.2.2 Design of an Appropriate Toxicology Program; 2.3.2.3 Single- and Repeat-Dose Toxicity Studies; 2.3.2.4 Safety of the Formulated Plasmid DNA; 2.3.2.5 Specific Safety Considerations; 2.3.2.6 Choice of Animal Model; 2.4 Special Issues 2.4.1 Comparability of Plasmid Gene Therapy Products2.4.2 Mixed Plasmid Preparations; 2.4.3 Plasmid Molecular Structure; 2.5 Biosafety Issues and Environmental Risk Assessment; References; 3 From Bulk to Delivery: Plasmid Manufacturing and Storage; 3.1 Introduction; 3.1.1 Gene Therapy; 3.1.2 DNA Vaccination; 3.2 Manufacturing of Plasmid DNA; 3.2.1 Bacterial Cultivation; 3.2.2 Plasmid DNA Purification; 3.2.3 Innovative Aspects in Plasmid Manufacturing; 3.3 Quality Control of Plasmid DNA Vectors; 3.3.1 Proteins, Ribonucleic Acid, and Lipopolysaccharides; 3.3.2 Chromosomal DNA 3.3.3 Plasmid Identity3.3.4 Plasmid Topology (Structural Homogeneity); 3.4 Plasmid Stability during Storage and Application; 3.4.1 Long-Term Stability of Plasmid DNA; 3.4.2 Lyophilization for Long-Term Storage; 3.4.3 Stability during Application; 3.5 Future Developments; References; 4 Minimized, CpG-Depleted, and Methylated DNA Vectors: Towards Perfection in Nonviral Gene Therapy; 4.1 Introduction; 4.2 The Mammalian Immune System as a Barrier to Nonviral Gene Delivery; 4.3 Strategies to Minimize DNA Vectors 4.3.1 Excision of a DNA Fragment Containing a Transgene Expression Cassette from Plasmid DNA4.3.2 Intramolecular Site-Specific Recombination Within a Bacterial Plasmid; 4.3.3 Synthesis of Minimized DNA Vectors by PCR; 4.3.4 Improvement of Minimized DNA Vector Yield and Purity; 4.4 Depletion of CpG Dinucleotides in the Bacterial Vector Backbone; 4.5 Methylation of CpG Dinucleotides in Plasmid DNA; 4.6 Towards an Ideal Nonviral Vector; 4.7 Conclusion; References; 5 Localized Nucleic Acid Delivery: A Discussion of Selected Methods; 5.1 Foreword; 5.2 Nucleic Acid Delivery - What For? 5.3 Nucleic Acid Delivery - How? |
| Record Nr. | UNINA-9910144557003321 |
| Weinheim, : Wiley-VCH, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
DNA pharmaceuticals [[electronic resource] ] : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef
| DNA pharmaceuticals [[electronic resource] ] : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2005 |
| Descrizione fisica | 1 online resource (277 p.) |
| Disciplina |
615.372
616.0796 |
| Altri autori (Persone) | SchleefM (Martin) |
| Soggetto topico |
DNA vaccines
Gene therapy Immunotherapy |
| ISBN |
1-280-85409-X
9786610854097 3-527-60753-6 3-527-60700-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
DNA Pharmaceuticals; Preface; Contents; List of Contributors; Abbreviations; 1 DNA Vaccines - An Overview; 1.1 Rationale for DNA Vaccines; 1.2 Preclinical Proof of Concept; 1.3 Clinical Trials; 1.4 Second-Generation Vaccines; 1.5 Conclusions; References; 2 DNA as a Pharmaceutical - Regulatory Aspects; 2.1 Introduction; 2.2 Quality Requirements for DNA used as a Gene Therapy Product; 2.2.1 Introduction; 2.2.2 Production and Purification; 2.2.2.1 Raw Materials; 2.2.2.2 Antibiotics; 2.2.2.3 Solvents; 2.2.2.4 Fermentation; 2.2.2.5 Purification; 2.2.3 Cell Banking System Procedures
2.2.3.1 Generation and Characterization of Master and Working Cell Banks2.2.4 Product Characterization and Quality Criteria; 2.2.4.1 Identity; 2.2.4.2 Purity; 2.2.4.3 Adventitious Agents; 2.2.4.4 Potency; 2.3 Safety Studies for Clinical Trials; 2.3.1 General Considerations; 2.3.2 Conduct of Preclinical Safety Studies; 2.3.2.1 Regulations; 2.3.2.2 Design of an Appropriate Toxicology Program; 2.3.2.3 Single- and Repeat-Dose Toxicity Studies; 2.3.2.4 Safety of the Formulated Plasmid DNA; 2.3.2.5 Specific Safety Considerations; 2.3.2.6 Choice of Animal Model; 2.4 Special Issues 2.4.1 Comparability of Plasmid Gene Therapy Products2.4.2 Mixed Plasmid Preparations; 2.4.3 Plasmid Molecular Structure; 2.5 Biosafety Issues and Environmental Risk Assessment; References; 3 From Bulk to Delivery: Plasmid Manufacturing and Storage; 3.1 Introduction; 3.1.1 Gene Therapy; 3.1.2 DNA Vaccination; 3.2 Manufacturing of Plasmid DNA; 3.2.1 Bacterial Cultivation; 3.2.2 Plasmid DNA Purification; 3.2.3 Innovative Aspects in Plasmid Manufacturing; 3.3 Quality Control of Plasmid DNA Vectors; 3.3.1 Proteins, Ribonucleic Acid, and Lipopolysaccharides; 3.3.2 Chromosomal DNA 3.3.3 Plasmid Identity3.3.4 Plasmid Topology (Structural Homogeneity); 3.4 Plasmid Stability during Storage and Application; 3.4.1 Long-Term Stability of Plasmid DNA; 3.4.2 Lyophilization for Long-Term Storage; 3.4.3 Stability during Application; 3.5 Future Developments; References; 4 Minimized, CpG-Depleted, and Methylated DNA Vectors: Towards Perfection in Nonviral Gene Therapy; 4.1 Introduction; 4.2 The Mammalian Immune System as a Barrier to Nonviral Gene Delivery; 4.3 Strategies to Minimize DNA Vectors 4.3.1 Excision of a DNA Fragment Containing a Transgene Expression Cassette from Plasmid DNA4.3.2 Intramolecular Site-Specific Recombination Within a Bacterial Plasmid; 4.3.3 Synthesis of Minimized DNA Vectors by PCR; 4.3.4 Improvement of Minimized DNA Vector Yield and Purity; 4.4 Depletion of CpG Dinucleotides in the Bacterial Vector Backbone; 4.5 Methylation of CpG Dinucleotides in Plasmid DNA; 4.6 Towards an Ideal Nonviral Vector; 4.7 Conclusion; References; 5 Localized Nucleic Acid Delivery: A Discussion of Selected Methods; 5.1 Foreword; 5.2 Nucleic Acid Delivery - What For? 5.3 Nucleic Acid Delivery - How? |
| Record Nr. | UNINA-9910829843803321 |
| Weinheim, : Wiley-VCH, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
DNA pharmaceuticals : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef
| DNA pharmaceuticals : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2005 |
| Descrizione fisica | 1 online resource (277 p.) |
| Disciplina | 616.07/96 |
| Altri autori (Persone) | SchleefM (Martin) |
| Soggetto topico |
DNA vaccines
Gene therapy Immunotherapy |
| ISBN |
1-280-85409-X
9786610854097 3-527-60753-6 3-527-60700-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
DNA Pharmaceuticals; Preface; Contents; List of Contributors; Abbreviations; 1 DNA Vaccines - An Overview; 1.1 Rationale for DNA Vaccines; 1.2 Preclinical Proof of Concept; 1.3 Clinical Trials; 1.4 Second-Generation Vaccines; 1.5 Conclusions; References; 2 DNA as a Pharmaceutical - Regulatory Aspects; 2.1 Introduction; 2.2 Quality Requirements for DNA used as a Gene Therapy Product; 2.2.1 Introduction; 2.2.2 Production and Purification; 2.2.2.1 Raw Materials; 2.2.2.2 Antibiotics; 2.2.2.3 Solvents; 2.2.2.4 Fermentation; 2.2.2.5 Purification; 2.2.3 Cell Banking System Procedures
2.2.3.1 Generation and Characterization of Master and Working Cell Banks2.2.4 Product Characterization and Quality Criteria; 2.2.4.1 Identity; 2.2.4.2 Purity; 2.2.4.3 Adventitious Agents; 2.2.4.4 Potency; 2.3 Safety Studies for Clinical Trials; 2.3.1 General Considerations; 2.3.2 Conduct of Preclinical Safety Studies; 2.3.2.1 Regulations; 2.3.2.2 Design of an Appropriate Toxicology Program; 2.3.2.3 Single- and Repeat-Dose Toxicity Studies; 2.3.2.4 Safety of the Formulated Plasmid DNA; 2.3.2.5 Specific Safety Considerations; 2.3.2.6 Choice of Animal Model; 2.4 Special Issues 2.4.1 Comparability of Plasmid Gene Therapy Products2.4.2 Mixed Plasmid Preparations; 2.4.3 Plasmid Molecular Structure; 2.5 Biosafety Issues and Environmental Risk Assessment; References; 3 From Bulk to Delivery: Plasmid Manufacturing and Storage; 3.1 Introduction; 3.1.1 Gene Therapy; 3.1.2 DNA Vaccination; 3.2 Manufacturing of Plasmid DNA; 3.2.1 Bacterial Cultivation; 3.2.2 Plasmid DNA Purification; 3.2.3 Innovative Aspects in Plasmid Manufacturing; 3.3 Quality Control of Plasmid DNA Vectors; 3.3.1 Proteins, Ribonucleic Acid, and Lipopolysaccharides; 3.3.2 Chromosomal DNA 3.3.3 Plasmid Identity3.3.4 Plasmid Topology (Structural Homogeneity); 3.4 Plasmid Stability during Storage and Application; 3.4.1 Long-Term Stability of Plasmid DNA; 3.4.2 Lyophilization for Long-Term Storage; 3.4.3 Stability during Application; 3.5 Future Developments; References; 4 Minimized, CpG-Depleted, and Methylated DNA Vectors: Towards Perfection in Nonviral Gene Therapy; 4.1 Introduction; 4.2 The Mammalian Immune System as a Barrier to Nonviral Gene Delivery; 4.3 Strategies to Minimize DNA Vectors 4.3.1 Excision of a DNA Fragment Containing a Transgene Expression Cassette from Plasmid DNA4.3.2 Intramolecular Site-Specific Recombination Within a Bacterial Plasmid; 4.3.3 Synthesis of Minimized DNA Vectors by PCR; 4.3.4 Improvement of Minimized DNA Vector Yield and Purity; 4.4 Depletion of CpG Dinucleotides in the Bacterial Vector Backbone; 4.5 Methylation of CpG Dinucleotides in Plasmid DNA; 4.6 Towards an Ideal Nonviral Vector; 4.7 Conclusion; References; 5 Localized Nucleic Acid Delivery: A Discussion of Selected Methods; 5.1 Foreword; 5.2 Nucleic Acid Delivery - What For? 5.3 Nucleic Acid Delivery - How? |
| Record Nr. | UNINA-9910876820303321 |
| Weinheim, : Wiley-VCH, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Minicircle and miniplasmid DNA vectors [[electronic resource] ] : the future of nonviral and viral gene transfer / / edited by Martin Schleef
| Minicircle and miniplasmid DNA vectors [[electronic resource] ] : the future of nonviral and viral gene transfer / / edited by Martin Schleef |
| Pubbl/distr/stampa | Weinheim, Germany, : Wiley-Blackwell, 2013 |
| Descrizione fisica | 1 online resource (259 p.) |
| Disciplina | 615.895 |
| Altri autori (Persone) | SchleefM (Martin) |
| Soggetto topico |
Gene therapy
Genetic vectors Plasmids |
| ISBN |
3-527-67042-4
1-299-24148-4 3-527-67043-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Minicircle and Miniplasmid DNA Vectors: The Future of Non-Viral and Viral Gene Transfer; Contents; List of Contributors; Preface; 1 Minicircle Patents: A Short IP Overview of Optimizing Nonviral DNA Vectors; 2 Operator-Repressor Titration: Stable Plasmid Maintenance without Selectable Marker Genes; 2.1 Introduction; 2.2 Antibiotics and Metabolic Burden; 2.3 The Mechanism of ORT; 2.4 ORT Strain Development; 2.5 ORT Miniplasmids; 2.6 DNA Vaccine and Gene Therapy Vectors; 2.7 ORT-VAC: Plasmid-Based Vaccine Delivery Using Salmonella enterica; 2.8 Recombinant Protein Expression
2.9 Conclusions and Future DevelopmentsReferences; 3 Selection by RNA-RNA Interaction: Maximally Minimized Antibiotic Resistance-Free Plasmids; 3.1 Gene Therapy and DNA Vaccines: Emerging Technologies; 3.1.1 Therapeutic Plasmids: General Design Principles; 3.2 Therapeutic Plasmids: Novel Design and the Problem of Selection; 3.2.1 Replication Control of ColE1-Type Plasmids as an Alternative Selection Marker; 3.2.2 The MINIback Concept: Selection by RNA-RNA Interaction; 3.2.3 Improved Production Processes by MINIback Plasmids; 3.2.4 Improving Sequence Composition; 3.2.5 Efficient Gene Transfer 3.3 Conclusions Acknowledgments; References; 4 Plasmid-Based Medicinal Products - Focus on pFAR: A Miniplasmid Free of Antibiotic Resistance Markers; 4.1 Introduction: Rationale for the Development of Biosafe DNA Plasmid Vectors; 4.2 Specific Requirements for the Use of DNA Product as Medicines; 4.2.1 Requirements for Plasmid Quality and Purity; 4.2.2 Requirements for the Removal of Antibiotic Resistance Markers from Plasmid DNA; 4.2.2.1 Requirements for Biosafe Plasmids; 4.2.2.2 Positive Impact on the Removal of Antibiotic Resistance Markers 4.2.2.3 Effect of Plasmid Size on Gene Transfer Efficiency In Vitro and In Vivo 4.3 Nonviral Gene Vectors Devoid of Antibiotic Resistance Markers; 4.3.1 Generalities; 4.3.2 Selection Systems Devoid of Antibiotic Resistance Markers; 4.3.2.1 Complementation of Host Auxotrophy by a Function-Encoded Plasmid; 4.3.2.2 The Operator-Repressor Titration (ORT) System; 4.3.2.3 Protein-Based Antidote/Poison Selection Systems; 4.3.2.4 RNA-Based Selection Marker; 4.3.2.5 Suppression of a Nonsense Mutation; 4.4 The pFAR Plasmid Family; 4.4.1 Description of the Antibiotic-Free Selection System 4.4.2 pFAR Vectors Promote Efficient Expression in Several Types of Mammalian Cells 4.4.2.1 In Vitro Transfection Study; 4.4.2.2 In Vivo Transfection Studies; 4.4.3 Concluding Remarks on the pFAR4 Biosafe Miniplasmid; 4.5 Concluding Remarks and Perspectives; Acknowledgments; References; 5 Plasmid DNA Concatemers: Influence of Plasmid Structure on Transfection Efficiency; 5.1 Introduction; 5.2 Plasmid DNA Topology and Size; 5.3 Plasmid DNA Concatemers; 5.4 Conclusions; Acknowledgments; References; 6 Analytical Tools in Minicircle Production; 6.1 Introduction 6.1.1 Gene Transfer for Therapy, Vaccination, and Stem Cells |
| Record Nr. | UNINA-9910141646903321 |
| Weinheim, Germany, : Wiley-Blackwell, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Minicircle and miniplasmid DNA vectors : the future of nonviral and viral gene transfer / / edited by Martin Schleef
| Minicircle and miniplasmid DNA vectors : the future of nonviral and viral gene transfer / / edited by Martin Schleef |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Weinheim, Germany, : Wiley-Blackwell, 2013 |
| Descrizione fisica | 1 online resource (259 p.) |
| Disciplina | 615.895 |
| Altri autori (Persone) | SchleefM (Martin) |
| Soggetto topico |
Gene therapy
Genetic vectors Plasmids |
| ISBN |
3-527-67042-4
1-299-24148-4 3-527-67043-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Minicircle and Miniplasmid DNA Vectors: The Future of Non-Viral and Viral Gene Transfer; Contents; List of Contributors; Preface; 1 Minicircle Patents: A Short IP Overview of Optimizing Nonviral DNA Vectors; 2 Operator-Repressor Titration: Stable Plasmid Maintenance without Selectable Marker Genes; 2.1 Introduction; 2.2 Antibiotics and Metabolic Burden; 2.3 The Mechanism of ORT; 2.4 ORT Strain Development; 2.5 ORT Miniplasmids; 2.6 DNA Vaccine and Gene Therapy Vectors; 2.7 ORT-VAC: Plasmid-Based Vaccine Delivery Using Salmonella enterica; 2.8 Recombinant Protein Expression
2.9 Conclusions and Future DevelopmentsReferences; 3 Selection by RNA-RNA Interaction: Maximally Minimized Antibiotic Resistance-Free Plasmids; 3.1 Gene Therapy and DNA Vaccines: Emerging Technologies; 3.1.1 Therapeutic Plasmids: General Design Principles; 3.2 Therapeutic Plasmids: Novel Design and the Problem of Selection; 3.2.1 Replication Control of ColE1-Type Plasmids as an Alternative Selection Marker; 3.2.2 The MINIback Concept: Selection by RNA-RNA Interaction; 3.2.3 Improved Production Processes by MINIback Plasmids; 3.2.4 Improving Sequence Composition; 3.2.5 Efficient Gene Transfer 3.3 Conclusions Acknowledgments; References; 4 Plasmid-Based Medicinal Products - Focus on pFAR: A Miniplasmid Free of Antibiotic Resistance Markers; 4.1 Introduction: Rationale for the Development of Biosafe DNA Plasmid Vectors; 4.2 Specific Requirements for the Use of DNA Product as Medicines; 4.2.1 Requirements for Plasmid Quality and Purity; 4.2.2 Requirements for the Removal of Antibiotic Resistance Markers from Plasmid DNA; 4.2.2.1 Requirements for Biosafe Plasmids; 4.2.2.2 Positive Impact on the Removal of Antibiotic Resistance Markers 4.2.2.3 Effect of Plasmid Size on Gene Transfer Efficiency In Vitro and In Vivo 4.3 Nonviral Gene Vectors Devoid of Antibiotic Resistance Markers; 4.3.1 Generalities; 4.3.2 Selection Systems Devoid of Antibiotic Resistance Markers; 4.3.2.1 Complementation of Host Auxotrophy by a Function-Encoded Plasmid; 4.3.2.2 The Operator-Repressor Titration (ORT) System; 4.3.2.3 Protein-Based Antidote/Poison Selection Systems; 4.3.2.4 RNA-Based Selection Marker; 4.3.2.5 Suppression of a Nonsense Mutation; 4.4 The pFAR Plasmid Family; 4.4.1 Description of the Antibiotic-Free Selection System 4.4.2 pFAR Vectors Promote Efficient Expression in Several Types of Mammalian Cells 4.4.2.1 In Vitro Transfection Study; 4.4.2.2 In Vivo Transfection Studies; 4.4.3 Concluding Remarks on the pFAR4 Biosafe Miniplasmid; 4.5 Concluding Remarks and Perspectives; Acknowledgments; References; 5 Plasmid DNA Concatemers: Influence of Plasmid Structure on Transfection Efficiency; 5.1 Introduction; 5.2 Plasmid DNA Topology and Size; 5.3 Plasmid DNA Concatemers; 5.4 Conclusions; Acknowledgments; References; 6 Analytical Tools in Minicircle Production; 6.1 Introduction 6.1.1 Gene Transfer for Therapy, Vaccination, and Stem Cells |
| Record Nr. | UNINA-9910813918003321 |
| Weinheim, Germany, : Wiley-Blackwell, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Plasmids for therapy and vaccination [[electronic resource] /] / edited by M. Schleef
| Plasmids for therapy and vaccination [[electronic resource] /] / edited by M. Schleef |
| Pubbl/distr/stampa | Weinheim ; ; New York, : Wiley-VCH, c2001 |
| Descrizione fisica | 1 online resource (308 p.) |
| Disciplina |
615.32
615.372 |
| Altri autori (Persone) | SchleefM (Martin) |
| Soggetto topico |
DNA vaccines
Gene therapy Plasmids |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-76398-5
9786611763985 3-527-61283-1 3-527-61284-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Plasmids for Therapy and Vaccination; Preface; Contents; List of Contributors; 1 The Biology of Plasmids; 1 Introduction: What are plasmids?; 2 General properties of plasmids; 2.1 Plasmid replication and its control; 2.2 The molecular basis of incompatibility; 2.3 Plasmid inheritance; 2.4 Mechanisms of plasmid spread; 2.4.1 Conjugation in gram-negative bacteria; 2.4.2 Conjugation in gram-positive bacteria; 3 Plasmid-encoded phenotypes; 3.1 Bacteriocin production and resistance; 3.2 The Ti plasmids; 3.3 Heavy metal resistance; 3.4 Other phenotypical traits
4 The clinical importance of plasmids4.1 The spread of antibiotic resistance and the evolution of multiple antibiotic resistance; 4.2 Transfer of antibiotic resistance genes; 4.3 Mechanisms of antibiotic resistance; 4.4 Bacterial virulence genes; 5 Plasmid cloning vectors; 6 Perspectives; References; 2 Structures of Plasmid DNA; 1 Introduction; 2 Topological structures of plasmids; 3 Supercoiling of DNA; 4 DNA intercalating dyes; 5 Analysis of plasmid structures; 5.1 Electron microscopy (EM); 5.2 Agarose gel electrophoresis (AGE); 5.3 Capillary gel electrophoresis (CGE) 5.4 Analytical chromatography6 Conclusion; References; 3 Genetic Vaccination with Plasmid Vectors; 1 Introduction; 2 Vector design; 2.1 Plasmid DNA; 2.2 Construction of simple transcription units; 2.3 Construction of complex transcription units; 3 Strategies for DNA delivery; 4 Priming humoral and cellular immune responses by DNA vaccines; 5 Experimental strategies facilitated by DNA vaccination; 6 Unique advantages of DNA vaccination; 7 DNA vaccines in preclinical animal models; 7.1 DNA vaccines to control infectious diseases; 7.2 Therapeutic tumor vaccines; 7.3 Autoimmune disease 7.4 Treatment of allergy by therapeutic DNA vaccination8 Proposed clinical applications of DNA vaccines; 9 Risks of nucleic acid vaccination; 10 Future perspectives; References; 4 A Liposomal iNOS-Gene Therapy Approach to Prevent Neointimal Lesion Formation in Porcine Femoral Arteries; 1 Introduction; 2 Results and discussion; 2.1 Therapeutic plasmid; 2.2 The gene therapy product has a clinically acceptable format; 2.3 Efficient gene transfer was established in a minipig femoral artery injury model; 2.4 Transfection efficiency is dose dependent 2.5 Non-viral iNOS gene transfer efficiently inhibits neointimal lesion formation3 Summary and perspectives; References; 5 lmmunotherapy of Chronic Hepatitis B by pCMV-S2.S DNA Vaccine; 1 Introduction; 1.1 Hepatitis B: the disease; 1.2 Hepatitis B: treatments; 1.3 Hepatitis B: immune response to infection; 1.4 What are DNA vaccines?; 1.5 Which DNA vaccines for hepatitis B?; 2 DNA vaccines for the prevention of hepatitis B; 2.1 The mouse model; 2.1.1 Humoral response; 2.1.2 Cell-mediated response; 2.1.3 Mechanisms of DNA-induced immune response to HBsAg; 2.1.4 The primate model 2.1.5 DNA-based vaccination of chimpanzees against HBV |
| Record Nr. | UNINA-9910144561703321 |
| Weinheim ; ; New York, : Wiley-VCH, c2001 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Plasmids for therapy and vaccination [[electronic resource] /] / edited by M. Schleef
| Plasmids for therapy and vaccination [[electronic resource] /] / edited by M. Schleef |
| Pubbl/distr/stampa | Weinheim ; ; New York, : Wiley-VCH, c2001 |
| Descrizione fisica | 1 online resource (308 p.) |
| Disciplina |
615.32
615.372 |
| Altri autori (Persone) | SchleefM (Martin) |
| Soggetto topico |
DNA vaccines
Gene therapy Plasmids |
| ISBN |
1-281-76398-5
9786611763985 3-527-61283-1 3-527-61284-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Plasmids for Therapy and Vaccination; Preface; Contents; List of Contributors; 1 The Biology of Plasmids; 1 Introduction: What are plasmids?; 2 General properties of plasmids; 2.1 Plasmid replication and its control; 2.2 The molecular basis of incompatibility; 2.3 Plasmid inheritance; 2.4 Mechanisms of plasmid spread; 2.4.1 Conjugation in gram-negative bacteria; 2.4.2 Conjugation in gram-positive bacteria; 3 Plasmid-encoded phenotypes; 3.1 Bacteriocin production and resistance; 3.2 The Ti plasmids; 3.3 Heavy metal resistance; 3.4 Other phenotypical traits
4 The clinical importance of plasmids4.1 The spread of antibiotic resistance and the evolution of multiple antibiotic resistance; 4.2 Transfer of antibiotic resistance genes; 4.3 Mechanisms of antibiotic resistance; 4.4 Bacterial virulence genes; 5 Plasmid cloning vectors; 6 Perspectives; References; 2 Structures of Plasmid DNA; 1 Introduction; 2 Topological structures of plasmids; 3 Supercoiling of DNA; 4 DNA intercalating dyes; 5 Analysis of plasmid structures; 5.1 Electron microscopy (EM); 5.2 Agarose gel electrophoresis (AGE); 5.3 Capillary gel electrophoresis (CGE) 5.4 Analytical chromatography6 Conclusion; References; 3 Genetic Vaccination with Plasmid Vectors; 1 Introduction; 2 Vector design; 2.1 Plasmid DNA; 2.2 Construction of simple transcription units; 2.3 Construction of complex transcription units; 3 Strategies for DNA delivery; 4 Priming humoral and cellular immune responses by DNA vaccines; 5 Experimental strategies facilitated by DNA vaccination; 6 Unique advantages of DNA vaccination; 7 DNA vaccines in preclinical animal models; 7.1 DNA vaccines to control infectious diseases; 7.2 Therapeutic tumor vaccines; 7.3 Autoimmune disease 7.4 Treatment of allergy by therapeutic DNA vaccination8 Proposed clinical applications of DNA vaccines; 9 Risks of nucleic acid vaccination; 10 Future perspectives; References; 4 A Liposomal iNOS-Gene Therapy Approach to Prevent Neointimal Lesion Formation in Porcine Femoral Arteries; 1 Introduction; 2 Results and discussion; 2.1 Therapeutic plasmid; 2.2 The gene therapy product has a clinically acceptable format; 2.3 Efficient gene transfer was established in a minipig femoral artery injury model; 2.4 Transfection efficiency is dose dependent 2.5 Non-viral iNOS gene transfer efficiently inhibits neointimal lesion formation3 Summary and perspectives; References; 5 lmmunotherapy of Chronic Hepatitis B by pCMV-S2.S DNA Vaccine; 1 Introduction; 1.1 Hepatitis B: the disease; 1.2 Hepatitis B: treatments; 1.3 Hepatitis B: immune response to infection; 1.4 What are DNA vaccines?; 1.5 Which DNA vaccines for hepatitis B?; 2 DNA vaccines for the prevention of hepatitis B; 2.1 The mouse model; 2.1.1 Humoral response; 2.1.2 Cell-mediated response; 2.1.3 Mechanisms of DNA-induced immune response to HBsAg; 2.1.4 The primate model 2.1.5 DNA-based vaccination of chimpanzees against HBV |
| Record Nr. | UNINA-9910830465703321 |
| Weinheim ; ; New York, : Wiley-VCH, c2001 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Plasmids for therapy and vaccination / / edited by M. Schleef
| Plasmids for therapy and vaccination / / edited by M. Schleef |
| Pubbl/distr/stampa | Weinheim ; ; New York, : Wiley-VCH, c2001 |
| Descrizione fisica | 1 online resource (308 p.) |
| Disciplina | 615/.3 |
| Altri autori (Persone) | SchleefM (Martin) |
| Soggetto topico |
DNA vaccines
Gene therapy Plasmids |
| ISBN |
1-281-76398-5
9786611763985 3-527-61283-1 3-527-61284-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Plasmids for Therapy and Vaccination; Preface; Contents; List of Contributors; 1 The Biology of Plasmids; 1 Introduction: What are plasmids?; 2 General properties of plasmids; 2.1 Plasmid replication and its control; 2.2 The molecular basis of incompatibility; 2.3 Plasmid inheritance; 2.4 Mechanisms of plasmid spread; 2.4.1 Conjugation in gram-negative bacteria; 2.4.2 Conjugation in gram-positive bacteria; 3 Plasmid-encoded phenotypes; 3.1 Bacteriocin production and resistance; 3.2 The Ti plasmids; 3.3 Heavy metal resistance; 3.4 Other phenotypical traits
4 The clinical importance of plasmids4.1 The spread of antibiotic resistance and the evolution of multiple antibiotic resistance; 4.2 Transfer of antibiotic resistance genes; 4.3 Mechanisms of antibiotic resistance; 4.4 Bacterial virulence genes; 5 Plasmid cloning vectors; 6 Perspectives; References; 2 Structures of Plasmid DNA; 1 Introduction; 2 Topological structures of plasmids; 3 Supercoiling of DNA; 4 DNA intercalating dyes; 5 Analysis of plasmid structures; 5.1 Electron microscopy (EM); 5.2 Agarose gel electrophoresis (AGE); 5.3 Capillary gel electrophoresis (CGE) 5.4 Analytical chromatography6 Conclusion; References; 3 Genetic Vaccination with Plasmid Vectors; 1 Introduction; 2 Vector design; 2.1 Plasmid DNA; 2.2 Construction of simple transcription units; 2.3 Construction of complex transcription units; 3 Strategies for DNA delivery; 4 Priming humoral and cellular immune responses by DNA vaccines; 5 Experimental strategies facilitated by DNA vaccination; 6 Unique advantages of DNA vaccination; 7 DNA vaccines in preclinical animal models; 7.1 DNA vaccines to control infectious diseases; 7.2 Therapeutic tumor vaccines; 7.3 Autoimmune disease 7.4 Treatment of allergy by therapeutic DNA vaccination8 Proposed clinical applications of DNA vaccines; 9 Risks of nucleic acid vaccination; 10 Future perspectives; References; 4 A Liposomal iNOS-Gene Therapy Approach to Prevent Neointimal Lesion Formation in Porcine Femoral Arteries; 1 Introduction; 2 Results and discussion; 2.1 Therapeutic plasmid; 2.2 The gene therapy product has a clinically acceptable format; 2.3 Efficient gene transfer was established in a minipig femoral artery injury model; 2.4 Transfection efficiency is dose dependent 2.5 Non-viral iNOS gene transfer efficiently inhibits neointimal lesion formation3 Summary and perspectives; References; 5 lmmunotherapy of Chronic Hepatitis B by pCMV-S2.S DNA Vaccine; 1 Introduction; 1.1 Hepatitis B: the disease; 1.2 Hepatitis B: treatments; 1.3 Hepatitis B: immune response to infection; 1.4 What are DNA vaccines?; 1.5 Which DNA vaccines for hepatitis B?; 2 DNA vaccines for the prevention of hepatitis B; 2.1 The mouse model; 2.1.1 Humoral response; 2.1.2 Cell-mediated response; 2.1.3 Mechanisms of DNA-induced immune response to HBsAg; 2.1.4 The primate model 2.1.5 DNA-based vaccination of chimpanzees against HBV |
| Record Nr. | UNINA-9910877064503321 |
| Weinheim ; ; New York, : Wiley-VCH, c2001 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||